首页> 美国卫生研究院文献>Medical Devices (Auckland N.Z.) >Bioresorbable adhesion barrier for reducing the severity of postoperative cardiac adhesions: Focus on REPEL-CV®
【2h】

Bioresorbable adhesion barrier for reducing the severity of postoperative cardiac adhesions: Focus on REPEL-CV®

机译:可生物吸收的粘连屏障可降低术后心脏粘连的严重程度:专注于REPEL-CV®

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Treatment of a number of congenital heart defects often necessitates staged surgical intervention. In addition, substantial improvements in postoperative cardiac care and more liberal use of biological valve substitutes have resulted in many adult patients surviving to become potential candidates for reoperations to repair or replace valves or to undergo additional revascularization procedures. In all these scenarios, surgeons are confronted with cardiac adhesions, leading to an increased surgical risk. Thus, bioresorbable adhesion barriers had become of increasing interest because they are easy to use, and safe and effective. This review focuses on the mechanisms by which REPEL-CV® prevents adhesive processes, as well as the development, design, and materials used, and also summarizes efficacy studies, clinical data, safety, and current role in therapy.
机译:许多先天性心脏缺陷的治疗通常需要分阶段的手术​​干预。此外,术后心脏保健的显着改善和生物瓣膜替代品的更广泛使用已导致许多成年患者幸存下来,成为重新手术以修复或更换瓣膜或接受其他血运重建程序的潜在候选人。在所有这些情况下,外科医生都面临心脏粘连,导致手术风险增加。因此,由于可生物吸收的粘附屏障易于使用,安全有效,因此越来越受到关注。这篇综述着重介绍REPEL-CV ®防止粘附过程的机制,以及开发,设计和使用的材料,并总结了功效研究,临床数据,安全性和目前的作用。治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号